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Bladder cancer is the 7th commonest cancer in the UK accounting for 5,369 deaths in 2014 
[1]. Over the last decade, despite improvements in other cancers, bladder cancer survival 
has remained static [2, 3]. Treatment of incurable metastatic disease remains challenging, 
with cisplatin-based combination chemotherapy providing only 14 months median survival 
[4]. Bladder cancer and its treatment can have a significant detrimental impact on patient 
quality of life and mental wellbeing [5-7], with reported patient experience and satisfaction 
scores worse than for other cancers [8, 9]. This may be compounded by variations in 
treatment utilisation throughout the UK [10]. 
 
To try to address this variation and provide clarity on acceptable standards in routine 
practice within the National Health Service (NHS) in England, the National Institute for 
Health and Care Excellence (NICE) published guidance in February 2015 (Bladder cancer: 
diagnosis and management, https://www.nice.org.uk/guidance/ng2 ) [2]. Within the 
guidance the wording of the final recommendations denotes the certainty with which they 
are made. The word ‘offer’ anticipates such interventions will be routinely undertaken, 
while ‘consider’ suggests less certain benefit, when ‘the healthcare professional should 
spend more time considering and discussing the options with the patient’. 
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The British Uro-Oncology Group (BUG), formed in 2004, is the only dedicated professional 
association for British uro-oncologists providing a forum for discussion on research and 
policy. The BUG 12th Annual Meeting undertook an interactive multidisciplinary panel 
discussion to determine adherence to key NICE guidance recommendations, based on pre-
specified questions to an audience of UK uro-oncologists, urologists and nurse specialists 
summarised here. 
 
Question 1: ‘Do you have a bladder cancer specific clinical nurse specialist (CNS)?’  
Whilst the guideline recommends offering the support of an experienced CNS who has 
undergone training in bladder cancer care, only 21/83 (25%) of participants indicated that 
they were able to offer this. From the panel discussion it was noted that most hospitals have 
general urology CNS provision but that these roles were often conceived to cover different 
tumour types, with difficulty in providing dedicated bladder cancer support. National Cancer 
Patient Experience Surveys demonstrate that people with bladder cancer had a poorer 
experience than those with other urological cancers, and were least likely to have been 
provided with a cancer specific CNS [8, 11]. As provision of a cancer specific CNS is 
associated with higher patient satisfaction scores [11], the panel felt this was an important 
recommendation and should be a key priority.  
 
Question 2: ‘What proportion of patients at your centre with localised muscle invasive 
bladder cancer (MIBC) have a discussion within both urology and oncology about 
treatment options?’ 
The NICE guideline recommends offering a choice of radical cystectomy or radiotherapy 
with a radiosensitiser to people with MIBC cancer for whom radical therapy is suitable, and 
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that this should be based on a discussion between the patient and both urologist and clinical 
oncologist. The guideline enshrines the concept that to become ‘informed’ a person 
requires a discussion about their treatment options delivered by the specialists that 
undertake them. Whilst it was recognised that a discussion with both urology and oncology 
may not be appropriate for certain patients, only 47/77 (61%) of participants indicated that 
>75% of their patients had a discussion with both specialties. The panel felt that both the 
survival benefit from neoadjuvant chemotherapy [12, 13], and evidence for bladder 
preservation by radical chemo-radiotherapy as an alternative to cystectomy in appropriately 
selected patients [14], made these discussions important. Although evidence is limited, the 
panel view was that both resource availability and entrenched positions (regarding value of 
surgery or radiotherapy) were likely contributory factors. 
  
Question 3: ‘Do you utilise FDG PET scans within routine staging for bladder cancer?’ 
Accurate staging is required to facilitate discussion of disease risk and the likelihood of cure 
from potential interventions. In one study FDG PET with CT upstaged 19.8% of patients, with 
8.5% having treatment changed from curative to palliative intent [15]. The guidance 
recommends considering its use for people with MIBC or high-risk non-muscle-invasive 
bladder cancer (NMIBC) before radical treatment if there are indeterminate findings on CT 
or MRI, or a high risk of metastatic disease (for example, T3b disease). Only 13/78 (17%) of 
participants indicated they used FDG PET scans for bladder cancer staging to guide 
management of locally advanced disease. The panel were not fully convinced of the utility of 
FDG PET, and felt further studies were warranted. Newer emerging PET tracers may prove 
more beneficial for patients in the future. 
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Question 4: ‘Do you offer neoadjuvant chemotherapy (NAC) in appropriate patients?’ 
The level 1 evidence in support of combination cisplatin based NAC demonstrates an 
absolute overall survival benefit of 5%. Despite this, concerns persist that NAC is 
underutilised [16]. In an audit of UK practice between 2004 and 2012 over a third with a 
suitable indication underwent NAC [17]. The NICE guidance recommends offering NAC to 
suitable newly diagnosed patients [18-20]. Encouragingly, 66/81 (81%) of participants 
indicated that they always gave NAC to ‘appropriate’ people, with all other responding 
participants indicating they ‘sometimes’ used it. Taking into account patient suitability, the 
panel were encouraged by the response to this question, suggesting increasing NAC use in 
the UK, although coverage may as yet be incomplete. 
 
Question 5: ‘Do you offer adjuvant chemotherapy (AC) in appropriate patients?’ and 
‘What would your criteria be for offering adjuvant chemotherapy?’ 
The evidence is stronger to support NAC (Level 1) compared to AC. For an adjuvant 
approach, a meta-analysis of 945 patients from nine controlled trials found that AC resulted 
in improved survival [21]. However on closer analysis, none of the analysed trials recruited 
to completion and some were unpublished. To date no single, methodologically adequate, 
phase III trial has been completed in this setting. The NICE guideline reflects this finding in 
its wording of ‘consider’ adjuvant cisplatin combination chemotherapy after radical 
cystectomy for people with a diagnosis of muscle-invasive or lymph-node-positive bladder 
cancer who were not eligible for neoadjuvant chemotherapy, thus positioning NAC as the 
standard approach but allows for AC, for example, after upstaging to MIBC at cystectomy. 
21/78 (27%) of participants always gave AC; 51% sometimes gave it. If, following radical 
cystectomy, the pathology was upstaged from NMIBC to MIBC, 22/73 (30%) of participants 
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indicated they would offer AC. While 60% would offer it to high risk patients that did not 
receive NAC, 10% would offer it to patients with persistent disease despite NAC. The panel 
felt there was little evidence to support the latter option. 
 
Question 7: ‘Do you routinely offer radiation with a radiosensitiser or radiotherapy alone, 
assuming the patient is fit for this?’ and ‘What is your choice of chemo-radiation 
regimen?’ 
Radiotherapy with a concurrent radiosensitiser improves outcomes over radiotherapy alone 
and the NICE guideline endorses this. Encouragingly, 61/74 (82%) of participants indicated 
that they routinely offered radiotherapy with a radiosensitiser over radiotherapy alone in 
suitable patients. Three main regimens are commonly utilised in the UK: 43/65 (65%) of 
participants indicated they would choose the BC2001 regimen (concurrent mitomycin C/5-
FU) [22], 22% would choose GemX (gemcitabine) [23] and 12% BCON 
(carbogen/nicotinamide) [24]. Whilst the responses imply widespread use of radiation with 
a radiosensitiser, it was not universal. The panel agreed that further research was required 
to determine the optimal approach. 
 
Question 9: ‘Other than a cisplatin based chemotherapy regimen if the patient is suitable, 
what other second line agents would you use?’ 
Second line treatments provide median progression-free survival of around 3-4 months [4, 
25], although only one phase III controlled trial is reported to date of vinflunine plus best 
supportive care (BSC) versus BSC alone in platinum-refractory disease, with no benefit in the 
primary endpoint (overall survival in the intent to treat population) [26]. Responses 
indicated that 42/47 (89%) of participants would choose single agent paclitaxel. The NICE 
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guideline recommends consideration of second line cisplatin-based chemotherapy in 
suitable patients, and in those not suitable, consideration of paclitaxel combined with 
carboplatin or gemcitabine. The panel felt that further research was warranted. Of note, the 
recent UK academic study, PLUTO, incorporated paclitaxel as the control arm in comparison 
to pazopanib in the second line setting. Despite early termination due to futility, it provided 
information on single agent paclitaxel in this setting, with an overall survival of 8.0 months 
and median PFS of 3.2 months [27]. 
 
Conclusions 
Mortality remains high in patients with MIBC and outcomes for advanced/metastatic 
disease remain poor. Furthermore, both bladder cancer and its treatments impact on 
quality of life. The NICE bladder cancer guideline was developed to clarify acceptable 
standards and address variation within NHS practice, so that equitable access to a consistent 
care standard would improve patient outcomes and satisfaction. Despite the obvious 
limitations of the data presented here , including selection bias of conference attendees 
compared to the wider community, we do feel that they provide an indication of practice 
patterns in the UK.  
 
In conclusion, we consider that variation in bladder cancer management could be reduced 
through adoption of the NICE bladder cancer clinical guideline. Further studies are 
warranted to explore adoption and identify if this impacts on patient satisfaction and 
outcomes. 
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